Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | Chief Financial Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,334 |
Reported balance
After 2024-01-02 transaction · row 1
1 source rowRow 1 · 2024-01-02 · Tax withholding · Disposed 382 · Balance 86,334 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IXYS, LLC
Report date January 17, 2018 · Filed January 18, 2018
Section 16 reporting ended · disclosed 2018-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 1
1 source rowRow 1 · 2018-01-17 · Disposition to issuer · Disposed 5,172 · Balance 0 F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.83 · Expires 2024-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2025-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2026-08-26 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock.
F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option.
F3: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · derivative · entry 14 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,749 Underlying: Common Stock · 30,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $64.85 | $12,969.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,719 Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 10,809 | $64.18 | $693,694.60 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,919 F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $63.77 to $64.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 17,491 | $63.34 | $1,107,865.95 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,728 F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $62.77 to $63.76 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,500 | $61.85 | $92,779.95 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,219 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $61.62 to $62.37 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 30,000 | $11.59 | $347,700.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:37 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 7,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-007683 · marketforms-49589.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,719 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2020, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 01, 2020 Filed May 23, 2023 16:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 23,355 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0001214659-23-007732 · marketforms-61596.xml · derivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,355 Underlying: Common Stock · 23,355 shares Expires 2030-08-31 F2 · balance_after: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 17:42 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $67.28 | $65,059.76 |
DisclosureSEC source: 0001214659-20-007449 · marketforms-49493.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,929 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 20, 2020 Filed May 22, 2020 21:08 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $39.76 | $38,447.92 |
DisclosureSEC source: 0001214659-20-004971 · marketforms-48848.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,572 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $33.13 | $32,036.71 |
DisclosureSEC source: 0001214659-20-001755 · marketforms-47854.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,070 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 18:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,868 | $22.85 | $88,383.80 |
DisclosureSEC source: 0001214659-19-007344 · marketforms-46380.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,037 Read SEC document |
| October 24, 2019 Filed Nov 5, 2019 21:29 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 35,740 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001209191-19-055412 · doc4.xml · derivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,740 Underlying: Common Stock · 35,740 shares Expires 2029-10-23 F3 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| October 24, 2019 Filed Nov 5, 2019 21:29 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 8,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055412 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,905 F1 · shares: Represents a restricted stock unit award (the "RSU Award") that vests in installments, with 25% of the shares subject to the RSU Award vesting on October 24, 2020 and 1/16th of the shares subject to the RSU Award vesting on each quarterly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · derivative · entry 15 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,749 Underlying: Common Stock · 3,500 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 250 | $30.45 | $7,613.50 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 13 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,002 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $30.25 | $15,125.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 12 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,252 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 250 | $30.46 | $7,614.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 11 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $30.47 | $15,233.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 10 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,002 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $30.14 | $15,072.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 9 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,502 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $30.31 | $15,156.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,002 Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,000 | $30.40 | $30,396.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,502 F1 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $30.39 to $30.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 3,500 | $11.59 | $40,565.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · derivative · entry 14 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,249 Underlying: Common Stock · 6,500 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,000 | $29.51 | $29,509.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,002 F1 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $29.44 to $29.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,000 | $29.58 | $29,581.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,002 F1 · shares: Represents the aggregate of sales effected on the same day at different prices. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $29.53 to $29.67 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,500 | $29.60 | $44,400.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,002 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,000 | $29.47 | $88,407.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,502 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 19:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,500 | $11.59 | $75,335.00 |
DisclosureSEC source: 0001209191-19-046897 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 17:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 91,004 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001209191-18-059802 · doc4.xml · derivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,004 Underlying: Common Stock · 91,004 shares Expires 2028-11-18 F2 · derivative.exercise_date: 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 17:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 39,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-059802 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,002 F1 · shares: Represents a restricted stock unit award (the "RSU Award") that vests in installments, with 12/60th of the shares subject to the RSU Award vesting on November 20, 2019 and 1/20th of the shares subject to the RSU Award vesting on each quarterly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 13:47 UTC | IXYS, LLC IXYS · Entity 170247 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $11.58 | Not disclosed |
DisclosureSEC source: 0000899243-18-001285 · doc4.xml · derivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-08-26 F2 · kind: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F2 · price: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 13:47 UTC | IXYS, LLC IXYS · Entity 170247 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $11.14 | Not disclosed |
DisclosureSEC source: 0000899243-18-001285 · doc4.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-08-28 F2 · kind: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F2 · price: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 13:47 UTC | IXYS, LLC IXYS · Entity 170247 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $11.83 | Not disclosed |
DisclosureSEC source: 0000899243-18-001285 · doc4.xml · derivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-08-28 F2 · kind: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F2 · price: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 13:47 UTC | IXYS, LLC IXYS · Entity 170247 | Disposition to issuerCommon Stock | 5,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-001285 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock. F1 · price: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.27 | $0.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · derivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2023-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,900 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · derivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 8,900 shares Expires 2021-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 5,000 | $23.65 | $118,250.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionCommon Stock | 5,000 | $9.27 | $46,350.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 8,620 | $23.65 | $203,863.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 280 | $23.75 | $6,650.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 16:41 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionCommon Stock | 8,900 | $12.25 | $109,025.00 |
DisclosureSEC source: 0001209191-17-064194 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:25 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001209191-17-064043 · doc4.xml · derivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,900 Underlying: Common Stock · 11,100 shares Expires 2021-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:25 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 1,100 | $23.80 | $26,180.00 |
DisclosureSEC source: 0001209191-17-064043 · doc4.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:25 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 10,000 | $23.95 | $239,500.00 |
DisclosureSEC source: 0001209191-17-064043 · doc4.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,272 Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:25 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionCommon Stock | 11,100 | $12.25 | $135,975.00 |
DisclosureSEC source: 0001209191-17-064043 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 16:25 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0001209191-17-038548 · doc4.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 20,000 shares Expires 2020-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 16:25 UTC | IXYS, LLC IXYS · Entity 170247 | SaleCommon Stock | 20,000 | $16.41 | $328,206.00 |
DisclosureSEC source: 0001209191-17-038548 · doc4.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 F1 · price: The shares were sold in multiple trades at prices ranging from $16.40 to $16.45. The price reported above is the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the shares were sold upon receipt of a request from the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 16:25 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionCommon Stock | 20,000 | $9.37 | $187,400.00 |
DisclosureSEC source: 0001209191-17-038548 · doc4.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 9, 2017 19:58 UTC | IXYS, LLC IXYS · Entity 170247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001209191-17-009318 · doc4.xml · derivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 5,000 shares Expires 2022-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.